Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fasiglifam - Takeda

Next Previous
X
Search
Drug Profile

Fasiglifam - Takeda

Alternative Names: TAK-875

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda
  • Class Antihyperglycaemics; Benzofurans; Small molecules; Sulfones
  • Mechanism of Action FFAR1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 27 Dec 2013 Discontinued - Phase-III for Type-2 diabetes mellitus (combination therapy) in USA, Argentina, Australia, Brazil, Bulgaria, Canada, Colombia, Croatia, the Czech Republic, Estonia, France, Germany, Hong Kong, Hungary, Israel, Italy, Latvia, Lithuania, Malaysia, Mexico, New Zealand, Peru, the Philippines, Poland, Romania, Russia, Slovakia, South Africa, South Korea, Thailand, Ukraine and United Kingdom (PO)
  • 27 Dec 2013 Discontinued - Phase-III for Type-2 diabetes mellitus (monotherapy) in Argentina, Bulgaria, Hungary, Guatemala, Mexico, Slovakia, Ukraine and USA (PO)
  • 27 Dec 2013 Discontinued - Phase-III for Type-2 diabetes mellitus in Australia, China, Japan, New Zealand, South Korea and Taiwan (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top